Key Points
- William Doyle sold 71,887 shares of NovoCure at an average price of $12.98 on March 3 for roughly $933,093, trimming his ownership by about 17.96% to 328,397 shares.
- Multiple other senior insiders (including the COO, CEO and CFO) also executed notable sales this week, a breadth of transactions that likely weighs on investor sentiment.
- Shares fell about 5.2% to $13.49; NovoCure reported Q EPS of ($0.22) that beat estimates and revenue of $174.35M (+8.2% y/y), but the company remains unprofitable and carries a consensus analyst rating of "Hold."
NovoCure Limited (NASDAQ:NVCR - Get Free Report) insider Michal Nath Puri sold 1,100 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total transaction of $14,641.00. Following the completion of the sale, the insider owned 201,322 shares in the company, valued at $2,679,595.82. This represents a 0.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
NovoCure Price Performance
Shares of NASDAQ:NVCR traded down $1.17 during trading on Friday, hitting $13.06. 595,481 shares of the company were exchanged, compared to its average volume of 2,193,560. NovoCure Limited has a 1-year low of $9.82 and a 1-year high of $21.55. The company has a market capitalization of $1.49 billion, a P/E ratio of -10.70 and a beta of 0.71. The company has a quick ratio of 1.50, a current ratio of 2.90 and a debt-to-equity ratio of 0.70. The business's 50 day moving average is $12.75 and its 200-day moving average is $12.71.
NovoCure (NASDAQ:NVCR - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.19. NovoCure had a negative return on equity of 39.11% and a negative net margin of 20.79%.The business had revenue of $174.35 million for the quarter, compared to analyst estimates of $174.40 million. During the same quarter in the previous year, the company posted ($0.61) EPS. NovoCure's quarterly revenue was up 8.2% compared to the same quarter last year. Equities analysts forecast that NovoCure Limited will post -1.3 earnings per share for the current year.
More NovoCure News
Here are the key news stories impacting NovoCure this week:
- Positive Sentiment: Q4 results beat consensus on EPS (reported ($0.22) vs. ($0.41) est.) and revenue rose ~8.2% year‑over‑year — a fundamental positive that supports the recovery narrative. MarketBeat NVCR coverage
- Positive Sentiment: Certain sell‑side firms remain upbeat (e.g., HC Wainwright raised its target and several analysts retain Buy ratings), providing upside scenarios versus the current price should clinical/ commercial momentum continue. Analyst notes (MarketBeat)
- Neutral Sentiment: Brokerage consensus is an overall “Hold,” indicating limited near‑term conviction for a re‑rating even though the average price target sits well above today’s level. NovoCure receives average "Hold" rating
- Neutral Sentiment: High institutional ownership (~84.6%) reduces free‑float but also concentrates voting power; large insider moves can therefore have outsized signaling effects. Institutional holdings (MarketBeat)
- Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k), trimming his stake by ~18% — a sizable single insider sale that the market often reads negatively. SEC filing: Doyle sale
- Negative Sentiment: Multiple senior execs (COO Mukund Paravasthu, CEO Frank Leonard, CFO Christoph Brackmann and others) executed notable sales in the same period — an aggregated pattern that likely amplified selling pressure and drove intraday weakness. Insider trades summary (SEC / MarketBeat)
Hedge Funds Weigh In On NovoCure
Hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley grew its holdings in NovoCure by 453.4% during the 4th quarter. Morgan Stanley now owns 5,069,895 shares of the medical equipment provider's stock worth $65,554,000 after acquiring an additional 4,153,741 shares during the period. Soleus Capital Management L.P. lifted its stake in NovoCure by 25.0% in the second quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider's stock valued at $122,897,000 after buying an additional 1,382,888 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of NovoCure by 1,093.2% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,223,755 shares of the medical equipment provider's stock worth $15,823,000 after buying an additional 1,121,192 shares in the last quarter. American Century Companies Inc. grew its position in shares of NovoCure by 1,354.7% during the 2nd quarter. American Century Companies Inc. now owns 1,029,874 shares of the medical equipment provider's stock worth $18,332,000 after buying an additional 959,079 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of NovoCure in the 4th quarter valued at $11,991,000. Institutional investors and hedge funds own 84.61% of the company's stock.
Analyst Ratings Changes
NVCR has been the topic of a number of research reports. Wedbush reissued a "neutral" rating and set a $18.00 target price on shares of NovoCure in a report on Thursday, January 15th. Weiss Ratings reissued a "sell (e+)" rating on shares of NovoCure in a research note on Thursday, January 22nd. HC Wainwright raised their target price on NovoCure from $47.00 to $49.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Finally, Evercore set a $20.00 target price on NovoCure in a report on Monday, January 5th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, NovoCure has a consensus rating of "Hold" and an average target price of $26.93.
Check Out Our Latest Stock Analysis on NovoCure
About NovoCure
(
Get Free Report)
NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company's non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure's approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.
Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
